HC Wainwright Analysts Decrease Earnings Estimates for TNGX

Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Research analysts at HC Wainwright dropped their Q1 2025 EPS estimates for Tango Therapeutics in a research report issued on Monday, April 14th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.35) for the quarter, down from their prior forecast of ($0.34). HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Tango Therapeutics' current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Tango Therapeutics' Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.52) EPS and FY2026 earnings at ($1.54) EPS.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The company had revenue of $4.12 million during the quarter, compared to the consensus estimate of $7.84 million.

Tango Therapeutics Trading Up 0.8 %

Shares of Tango Therapeutics stock traded up $0.01 on Wednesday, reaching $1.29. 467,141 shares of the company were exchanged, compared to its average volume of 1,072,447. The company has a market capitalization of $139.46 million, a price-to-earnings ratio of -1.09 and a beta of 1.03. The company has a 50-day moving average of $1.79 and a 200 day moving average of $3.29. Tango Therapeutics has a one year low of $1.11 and a one year high of $12.02.

Institutional Investors Weigh In On Tango Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Dynamic Technology Lab Private Ltd bought a new stake in shares of Tango Therapeutics during the 4th quarter worth about $33,000. Stonebrook Private Inc. bought a new stake in shares of Tango Therapeutics during the fourth quarter worth approximately $34,000. Ameriprise Financial Inc. acquired a new position in shares of Tango Therapeutics in the fourth quarter valued at approximately $35,000. Sherbrooke Park Advisers LLC bought a new position in shares of Tango Therapeutics during the fourth quarter worth approximately $38,000. Finally, Squarepoint Ops LLC acquired a new stake in Tango Therapeutics during the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 78.99% of the company's stock.

Insider Activity

In other Tango Therapeutics news, CEO Barbara Weber sold 9,778 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total value of $29,236.22. Following the sale, the chief executive officer now owns 1,631,264 shares in the company, valued at $4,877,479.36. This represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last ninety days, insiders have sold 24,268 shares of company stock valued at $72,561. 6.30% of the stock is owned by company insiders.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.